At CAMP4, we’re focused on harnessing the power of #RNA to restore healthy #GeneExpression and amplify protein production. By targeting #regRNAs, we’re pioneering a novel therapeutic approach for diseases with few or no treatment options. Learn more: bit.ly/3G3R8Y3

Our RAP Platform™ produces #regRNA-targeting therapies to upregulate #GeneExpression and restore healthy protein levels. This approach has the potential to treat a broad range of genetic diseases, including #SYNGAP1-related disorders. Learn more: bit.ly/3RF8vRx

On #WorldRNADay, we celebrate the core controller of gene expression and the center of our work. Using our RAP Platform™, our #regRNA-targeting therapies aim to upregulate #GeneExpression to treat a number of genetic diseases. Learn more: bit.ly/3G3R8Y3

Our CEO, Josh Mandel-Brehm, spoke with Damian Doherty at Inside Precision Medicine about the potential of our #regRNA-targeting therapies to address +1,200 diseases, like #SYNGAP1-related disorders. Learn about our strategy to upregulate #GeneExpression here: bit.ly/4mpDEWg

#ICYMI, our CEO, Josh Mandel-Brehm spoke with Reece Armstrong in this Drug Discovery World article to explore the science behind our #regRNA-targeting therapeutics and the potential of upregulating #GeneExpression to treat genetic diseases. Read more: bit.ly/41jV0Mn

Our CFO, Kelly Gold, is participating in a fireside chat at Piper Sandler’s Virtual CNS Symposium moderated by Ted Tenthoff. Tune in Thursday, August 14, from 1-1:25pm ET to hear our aim of restoring #GeneExpression to treat genetic diseases. More here: bit.ly/4oELIVd

Today we reported our Q2 financial results and corporate highlights. Read more in our press release: bit.ly/45yiQ85

#ICYMI, Anna Rose Welch features our SVP Tech Ops, Satya Kuchimanchi, PhD, in the recent Advancing #RNA article exploring the evolving landscape of ASO manufacturing and how innovation is shaping the future of oligonucleotide manufacturing. Read more: advancingrna.com/doc/moving-bey…

Our SVP Tech Ops, Satya Kuchimanchi, PhD, is presenting at the 4th Oligonucleotide Analytical Development & CMC Summit in #Boston from August 25-27. Learn more and register here: oligos-cmc-analytical-development.com

In this Advancing RNA article, Anna Rose Welch speaks with our SVP of Tech Ops, Satya Kuchimanchi, PhD, about the #RNA synthesis spectrum, including the basics of solid phase synthesis and the evolution and impact made throughout its discovery. More here: bit.ly/45QvorA

#regRNAs are the core controllers of gene expression. At CAMP4, we're pioneering an approach targeting regRNAs to upregulate #GeneExpression and restore healthy protein levels to offer potential treatments for a wide range of genetic diseases. Learn more: camp4tx.com/rna-actuators/

We are pleased to announce an oversubscribed private placement of up to $100 million to further fund development of a potential first-in-class treatment for #SYNGAP1-related disorders. Read more in our press release: bit.ly/42qhnjs

Looking forward to attending "Beacon of Hope" Benefit event hosted by SynGAP Research Fund (SRF), an opportunity to shine light on the strength of the #SYNGAP1 community & help raise awareness for the families & advocates who are at the center of our mission. More here: bit.ly/3JXozNT

#ICYMI: Our CEO, Josh Mandel-Brehm, spoke at the Cantor Global Healthcare Conference. Tune in as he highlights how our RAP Platform® targets #regRNAs to control #GeneExpression to treat genetic disorders, such as #SYNGAP1: bit.ly/4pBv4q3

We had a lovely time at the "Beacon of Hope" Benefit for the #SYNGAP1 community! Thank you to SynGAP Research Fund (SRF) for bringing everyone together around your meaningful cause & for providing a platform to engage in insightful conversations. Donate here to support: bit.ly/47otPnm

#ICYMI, our SVP, Head of Discovery, Dan Tardiff, PhD, spoke at the 5th Annual Oligonucleotides for CNS Summit hosted by Hanson Wade. He discussed the aim of our RAP Platform® to upregulate #GeneExpression to treat #SYNGAP1-related disorders. Thanks for an engaging event!

Today, we announced the initiation of toxicology studies conducted under Good Laboratory Practice (GLP) standards for our lead candidate for #SYNGAP1-related disorders, marking a critical step in our anticipated advancement towards the clinic. Read more: bit.ly/4oj1Hr5

Join us in congratulating Daniel Tardiff, PhD, on his promotion to CSO, and Alla Sigova, PhD, on her promotion to SVP, Platform! We thank David Bumcrot, PhD, for his impactful leadership as former CSO and welcome him to his new role as Scientific Fellow.

ICMYI: Our CMO, Yuri Maricich, MD, spoke at the @KCNQ2Cure 2025 Summit about our #regRNA-based therapeutics designed to upregulate #GeneExpression for treating developmental and epileptic encephalopathy (DEE), like #SYNGAP1-related disorders. Learn more: bit.ly/4pRc9Yf

Our CSO, Daniel Tardiff, PhD, will be presenting at the Oligonucleotide Therapeutics Society (OTS) Meeting on October 20. Here, he'll discuss how we identify and target tunable #regRNAs to develop ASOs with the potential to address #SYNGAP1-related disorders. More information here: bit.ly/4h8rXSm